WVEWave Life Sciences Ltd.

Nasdaq wavelifesciences.com


$ 5.69 $ 0.07 (1.25 %)    

Monday, 13-May-2024 15:59:58 EDT
QQQ $ 442.84 $ 1.02 (0.23 %)
DIA $ 394.52 $ -0.72 (-0.18 %)
SPY $ 520.61 $ 0.07 (0.01 %)
TLT $ 90.36 $ 0.23 (0.26 %)
GLD $ 216.28 $ -2.45 (-1.12 %)
$ 5.69
$ 5.76
$ 5.69 x 300
$ 0.00 x 0
$ 5.56 - $ 5.81
$ 3.15 - $ 7.67
625,212
na
735.56M
$ 0.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-06-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-03-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-04-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-02-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 03-01-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 03-12-2018 12-31-2017 10-K
27 11-09-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 03-16-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-15-2016 06-30-2016 10-Q
33 05-16-2016 03-31-2016 10-Q
34 03-30-2016 12-31-2015 10-K
35 12-17-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wave-life-sciences-q1-eps-024-misses-021-estimate-sales-1254m-miss-2295m-estimate

WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $...

 wave-life-sciences-announces-approval-of-first-clinical-trial-application-for-restoraation-2-trial-of-wve-006-in-individuals-with-alpha-1-antitrypsin-deficiency

Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA me...

Core News & Articles

GSK has selected the first two programs to advance following achievement of target validation, marking transition to next pha...

 truist-securities-reiterates-buy-on-wave-life-sciences-maintains-17-price-target

Truist Securities analyst Joon Lee reiterates WAVE Life Sciences (NASDAQ:WVE) with a Buy and maintains $17 price target.

 mizuho-maintains-buy-on-wave-life-sciences-raises-price-target-to-19

Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and raises the price target from $10 to $19.

 why-highpeak-energy-shares-are-trading-lower-by-15-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-exp...

 american-eagle-reports-upbeat-earnings-joins-kroger-burlington-stores-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Thursday.

 rbc-capital-reiterates-sector-perform-on-wave-life-sciences-maintains-5-price-target

RBC Capital analyst Luca Issi reiterates WAVE Life Sciences (NASDAQ:WVE) with a Sector Perform and maintains $5 price target.

 hc-wainwright--co-maintains-buy-on-wave-life-sciences-raises-price-target-to-15

HC Wainwright & Co. analyst Andrew Fein maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and raises the price target...

 why-united-natural-foods-shares-are-trading-lower-by-15-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

 box-reports-upbeat-earnings-joins-american-public-education-wave-life-sciences-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.

 wave-life-sciences-q4-eps-015-beats-023-estimate-sales-2906m-beat-1986m-estimate

WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0...

 earnings-scheduled-for-march-6-2024

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue o...

 wave-life-sciences-announces-upcoming-presentations-at-mda-conference-that-highlight-best-in-class-potential-for-wve-n531-in-duchenne-muscular-dystrophy

Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satel...

 165m-bet-on-this-healthcare-stock-check-out-these-4-stocks-insiders-are-buying

Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.

 leerink-partners-upgrades-wave-life-sciences-to-outperform-announces-12-price-target

Leerink Partners analyst Mani Foroohar upgrades WAVE Life Sciences (NASDAQ:WVE) from Market Perform to Outperform and announ...

 wave-life-sciences-announced-the-initiation-of-dosing-in-the-phase-2-forward-53-clinical-trial-which-is-evaluating-wve-n531-as-a-treatment-for-boys-with-duchenne-muscular-dystrophy-who-are-amenable-to-exon-53-skipping

FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024Previous clinical proof...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION